* 中国康方生物9926.HK周三早盘涨幅扩大至13.1%，创2020年上市以来新高。
* 该公司此前公告称，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非 小细胞肺癌的III期头对头临床试验达到PFS（无进展生存期）显著阳性结果，具有统计学显著意义和重大临床获益。
* 康方生物今年迄今劲涨54.7%，同期恒生指数.HSI大幅上扬10%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升3.8%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.